Literature DB >> 22157657

Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.

Sanjeev Sethi1, Carla M Nester, Richard J H Smith.   

Abstract

Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury that is easily recognized by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition that are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, while immunofluorescence typically detects immunoglobulins in MPGN I and MPGN III but not in MPGN II. All three MPGN types stain positive for complement component 3 (C3). Subgrouping has led to unnecessary confusion, primarily because immunoglobulin-negative MPGN I and MPGN III are more common than once recognized. Together with MPGN II, which is now called dense deposit disease, immunoglobulin-negative, C3-positive glomerular diseases fall under the umbrella of C3 glomerulopathies (C3G). The evaluation of immunoglobulin-positive MPGN should focus on identifying the underlying trigger driving the chronic antigenemia or circulating immune complexes in order to begin disease-specific treatment. The evaluation of C3G, in contrast, should focus on the complement cascade, as dysregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no disease-specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22157657      PMCID: PMC4428602          DOI: 10.1038/ki.2011.399

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  28 in total

1.  C3 deposition glomerulopathy due to a functional factor H defect.

Authors:  Sandra Habbig; Michael J Mihatsch; Stefan Heinen; Bodo Beck; Mathias Emmel; Christine Skerka; Michael Kirschfink; Bernd Hoppe; Peter F Zipfel; Christoph Licht
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

Review 2.  Complement regulators and inhibitory proteins.

Authors:  Peter F Zipfel; Christine Skerka
Journal:  Nat Rev Immunol       Date:  2009-09-04       Impact factor: 53.106

3.  Allelic variants of complement genes associated with dense deposit disease.

Authors:  Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 10.121

4.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Authors:  Aude Servais; Véronique Frémeaux-Bacchi; Moglie Lequintrec; Rémi Salomon; Jacques Blouin; Bertrand Knebelmann; Jean-Pierre Grünfeld; Philippe Lesavre; Laure-Hélène Noël; Fadi Fakhouri
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

Review 5.  Dense deposit disease.

Authors:  Richard J H Smith; Claire L Harris; Matthew C Pickering
Journal:  Mol Immunol       Date:  2011-05-24       Impact factor: 4.407

6.  Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.

Authors:  Sanjeev Sethi; Ladan Zand; Nelson Leung; Richard J H Smith; Dragan Jevremonic; Sandra S Herrmann; Fernando C Fervenza
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

7.  Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.

Authors:  Rubén Martínez-Barricarte; Meike Heurich; Francisco Valdes-Cañedo; Eduardo Vazquez-Martul; Eva Torreira; Tamara Montes; Agustín Tortajada; Sheila Pinto; Margarita Lopez-Trascasa; B Paul Morgan; Oscar Llorca; Claire L Harris; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2010-09-13       Impact factor: 14.808

8.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

Authors:  C Licht; S Heinen; M Józsi; I Löschmann; R E Saunders; S J Perkins; R Waldherr; C Skerka; M Kirschfink; B Hoppe; P F Zipfel
Journal:  Kidney Int       Date:  2006-04-12       Impact factor: 10.612

9.  Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.

Authors:  Daniel P Gale; Elena Goicoechea de Jorge; H Terence Cook; Rubén Martinez-Barricarte; Andreas Hadjisavvas; Adam G McLean; Charles D Pusey; Alkis Pierides; Kyriacos Kyriacou; Yiannis Athanasiou; Konstantinos Voskarides; Constantinos Deltas; Andrew Palmer; Véronique Frémeaux-Bacchi; Santiago Rodriguez de Cordoba; Patrick H Maxwell; Matthew C Pickering
Journal:  Lancet       Date:  2010-08-25       Impact factor: 79.321

Review 10.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more
  70 in total

1.  Eculizumab for dense deposit disease and C3 glomerulonephritis.

Authors:  Andrew S Bomback; Richard J Smith; Gaetano R Barile; Yuzhou Zhang; Eliot C Heher; Leal Herlitz; M Barry Stokes; Glen S Markowitz; Vivette D D'Agati; Pietro A Canetta; Jai Radhakrishnan; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

2.  Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3.

Authors:  Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2012-05-16       Impact factor: 8.860

Review 3.  Differential diagnosis of glomerular disease: a systematic and inclusive approach.

Authors:  Lee A Hebert; Samir Parikh; Jason Prosek; Tibor Nadasdy; Brad H Rovin
Journal:  Am J Nephrol       Date:  2013-09-13       Impact factor: 3.754

4.  American Society of Nephrology clinical pathological conference.

Authors:  Kevin E Meyers; Helen Liapis; Mohamed G Atta
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

5.  Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.

Authors:  Marie Nakano; Kazunori Karasawa; Takahito Moriyama; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2019-03-11       Impact factor: 2.801

6.  Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015.

Authors:  Naoki Nakagawa; Naoyuki Hasebe; Motoshi Hattori; Michio Nagata; Hitoshi Yokoyama; Hiroshi Sato; Hitoshi Sugiyama; Akira Shimizu; Yoshitaka Isaka; Shoichi Maruyama; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-12-06       Impact factor: 2.801

7.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Kidney Int       Date:  2018-05-03       Impact factor: 10.612

8.  C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; An S De Vriese; Sanjeev Sethi
Journal:  Mayo Clin Proc       Date:  2018-08       Impact factor: 7.616

Review 9.  Primary disease recurrence—effects on paediatric renal transplantation outcomes.

Authors:  Justine Bacchetta; Pierre Cochat
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

10.  C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.

Authors:  Neetika Garg; Yuzhou Zhang; Anne Nicholson-Weller; Eliyahu V Khankin; Nicolò Ghiringhelli Borsa; Nicole C Meyer; Susan McDermott; Isaac E Stillman; Helmut G Rennke; Richard J Smith; Martha Pavlakis
Journal:  Nephrol Dial Transplant       Date:  2018-12-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.